These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 415967)

  • 1. Allograft cytotoxicity. Two populations of effector cell detectable by cytolytic and cytostatic assays in vitro.
    Jones B; Jones TC; Roitt IM
    Immunology; 1977 Apr; 32(4):591-9. PubMed ID: 415967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allograft cytotoxicity co-operation between alloimmune T cells and macrophages.
    Jones B; Jones TC
    Immunology; 1978 Feb; 34(2):247-55. PubMed ID: 414994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allograft cytotoxicity. Role of T lymphocytes bearing a receptor for complement.
    Arnaiz-Villena A; Jones B; Roitt IM
    Immunology; 1975 Nov; 29(5):903-8. PubMed ID: 811554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.
    Germain RN; Williams RM; Benacerraf B
    Am J Pathol; 1976 Dec; 85(3):661-74. PubMed ID: 826167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of the effector cells mediating cytotoxicity against antibody-coated target cells. I. Phagocytic and non-phagocytic effector cell activity against erythrocyte and tumour target cells in a 51Cr release cytotoxicity assay and [125I]IUdR growth inhibition assay.
    Greenberg AH; Shen L; Medley G
    Immunology; 1975 Oct; 29(4):719-29. PubMed ID: 810417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific and nonspecific antitumor immunity. I. Description of an in vitro assay based on inhibition of DNA synthesis in tumor cells.
    Williams RM; Germain RN; Benacerraf B
    J Natl Cancer Inst; 1975 Mar; 54(3):697-708. PubMed ID: 1091740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of phorbol esters on alloimmune cytolysis.
    Munger WE; Lindquist RR
    Cancer Res; 1982 Dec; 42(12):5023-9. PubMed ID: 6814749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional activity in vivo of effector T cell populations. II. Anti-tumor activity exhibited by syngeneic anti-MoMULV-specific cytolytic T cell clones.
    Engers HD; Lahaye T; Sorenson GD; Glasebrook AL; Horvath C; Brunner KT
    J Immunol; 1984 Sep; 133(3):1664-70. PubMed ID: 6205090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction and properties of cytotoxic T cells specific for hapten-coupled tumor cells.
    Dennert G; Hatlen LE
    J Immunol; 1975 Jun; 114(6):1705-12. PubMed ID: 805174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of cell-mediated alloimmunity by BCG. II. Induction of specific, nonadherent, non-T-killer cells by BCG and alloantigen.
    Murahata RI; Mitchell MS
    J Natl Cancer Inst; 1982 Sep; 69(3):613-8. PubMed ID: 6810008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differing contribution of various effector cells in the elimination of syngeneic or allogeneic cells.
    Matsumoto T; Himeno K; Mitani M; Mori K; Miake S; Nomoto K
    J Clin Lab Immunol; 1986 Feb; 19(2):83-9. PubMed ID: 3083105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lectin-induced nonlethal adhesions between cytolytic T lymphocytes and antigenically unrecognizable tumor cells and nonspecific "triggering" of cytolysis.
    Parker WL; Martz E
    J Immunol; 1980 Jan; 124(1):25-35. PubMed ID: 6765968
    [No Abstract]   [Full Text] [Related]  

  • 13. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M; Orosz CG; Bach FH
    J Immunol; 1984 Jun; 132(6):3218-25. PubMed ID: 6202778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of in vivo generation of cytotoxic effector cells against tumor in tumor-bearing mice.
    Fuyama S; Yamamoto H; Fujii Y; Arai S
    Cancer Res; 1986 Nov; 46(11):5548-52. PubMed ID: 2428480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effector mechanism of tumor immunity in murine plasmacytoma.
    Chen YH; Anderson AB
    Cancer Res; 1988 Mar; 48(6):1398-403. PubMed ID: 3257896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific reversal of cytolytic T cell-target cell functional binding is induced by free target cells.
    Balk SP; Mescher MF
    J Immunol; 1981 Jul; 127(1):51-7. PubMed ID: 6787131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative studies of the growth and rejection of allogeneic tumour cells in mouse cerebrospinal fluid. Elimination in the absence of H-2 differences.
    Doherty PC; Zinkernagel RM
    Clin Exp Immunol; 1975 Feb; 19(2):355-66. PubMed ID: 813923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-reacting antigens on L5178Y cells which serve as targets for cytotoxic T-lymphocyte lysis during establishment of the tumor dormant state.
    Weinhold KJ; Wheelock EF
    Cancer Res; 1982 Sep; 42(9):3607-16. PubMed ID: 6179603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on T cell clonal expansion. I. Suppression of killer T cell production in vivo.
    Kamat R; Henney CS
    J Immunol; 1975 Dec; 115(6):1592-8. PubMed ID: 810513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific reversal of cytolytic T lymphocyte--target cell interaction.
    Balk SP; Mescher MF
    J Supramol Struct Cell Biochem; 1981; 16(1):43-52. PubMed ID: 6795359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.